Global Enalaprilat Injections Market Size, Share, and Trends Analysis Report, By Application (Hypertension, Ventricular Dysfunction, and Congestive Heart Failures) and By Distribution Channel (Hospital Pharmacies and Retail Drug Stores), Forecast (2022-2028)

The global enalaprilat injections market is anticipated to grow at a considerable CAGR 4% during the forecast period (2022-2028). Enalaprilat injections are ACE inhibitors that are used alone or in combination with other medicines for the treatment of the symptoms of high blood pressure, left ventricular dysfunction, and congestive heart failure. The major factor attributing to the growth of the global enalaprilat injections market includes the rising prevalence of hypertension (high blood pressure) across the globe. According to the Centers for Disease Control and Prevention (CDC), around 116 million have high blood pressure in the US alone representing around 47% of the total adult population of the country. Having high blood pressure can increase the risk of heart disease and heart strokes which can be the major cause of mortality. More than 5 million mortalities were caused due to hypertension in the US in 2019. Only one in every 4 adults with high blood pressure has their condition under control and more than half of the adults with high blood pressure have uncontrolled conditions. Thus, boosting the demand for enalaprilat injections.

In addition, the application of enalaprilat injections for the treatment of symptoms of congestive heart failure is also increasing due to the rising prevalence of congestive heart failure. According to the Heart Failure Society of America (HFSA), around 5.5 million new cases of congestive heart failure are diagnosed every year in the US alone with around 5 million people living with congestive heart failure in the country. Congestive heart failure can affect people of all ages including children, adults, and elders. Around 1.4 million people with congestive heart failure are under the age of 60 years and after 60 years of age, the prevalence of congestive heart failure is around 10 in every 1,000 people. Furthermore, enalaprilat injects are also used for the treatment of left ventricular dysfunction due to the benefit of getting injected intravenously for people who cannot take the medication through the oral route of administration.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc. Hikma Pharmaceuticals PLC, Novartis International AG, SteriMax Inc., and Teva Pharmaceuticals Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Enalaprilat Injections  Market Report by Segment

By Application

• Hypertension
• Ventricular Dysfunction
• Congestive Heart Failures

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores